Article Text

Download PDFPDF

2022-RA-1020-ESGO Family history in BRCA mutation carriers affected by breast and ovarian cancer and its role in identifying subjects at high risk
  1. Serena Negri1,
  2. Elena de Ponti2,
  3. Federica Paola Sina3,
  4. Elena Sala4,
  5. Cristina Dell’Oro1,
  6. Gaia Roversi4,
  7. Sara Lazzarin1,
  8. Martina Delle Marchette1,
  9. Alessandra Inzoli1,
  10. Claudia Toso5,
  11. Simona Fumagalli1,
  12. Ornella Campanella6,
  13. Joanne Kotsopoulos7,8 and
  14. Robert Fruscio1,3
  1. 1Clinic of Obstetrics and Gynaecology, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
  2. 2Department of Physical Medicine, ASST Monza, San Gerardo Hospital, Monza, Italy
  3. 3UOC Gynecologic Surgery, ASST Monza, San Gerardo Hospital, Monza, Italy
  4. 4UO Medical Genetics, ASST Monza, San Gerardo Hospital, Monza, Italy
  5. 5UOC Gestione Sanitaria delle Convenzioni, ATS Brianza, Lecco, Italy
  6. 6President of aBRCAdabra ONLUS, Italian advocacy BRCA genes mutation, Italy
  7. 7Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada
  8. 8Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada


Introduction/Background BRCA1 and BRCA2 mutations are the most common cause of hereditary breast and ovarian cancer, and are also associated with an increased risk of prostate and pancreatic cancer.Many guidelines have been provided over time to identify BRCA mutation carriers, and they are usually based on a suggestive personal and family history (FH) of cancer. Addressing affected patients to genetic counseling can lead to therapeutic benefits, however identifying healthy high risk individuals before they develop cancer could give them the opportunity to access appropriate surveillance and risk-reducing treatments.

Methodology We applied the family history (FH) criteria proposed by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the Italian Association of Medical Oncology (AIOM) guidelines to the FH of 157 women who found out to be BRCA mutations carriers after a diagnosis of breast or ovarian cancer.

Results A FH of BRCA-related cancer was found in almost 85% of women. NCCN and AIOM FH criteria would have detected 63.6% and 52.2% of patients respectively before tumor diagnosis (p<0,05). The most frequent criteria were a FH of ovarian cancer and of breast cancer diagnosed <45 years old. 65% of the women who died from progression of disease would have been eligible for testing based on their FH.

Conclusion Family history should always be investigated and specific sets of criteria should be included in guidelines independently from a personal history of cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.